AstraZeneca Pharma
AstraZeneca Pharma
HealthcareKey Fundamentals
SmallcapPharmaceuticalsHealthcareTapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
1- Company has been maintaining a healthy dividend payout of 51.4%
Weaknesses
1- Stock is trading at 19.4 times its book value
Growth Rate
AI Analysis — Bull vs Bear
anthropic claude-opus-4.6 2d agoAstrazeneca Pharma India Ltd, with a market cap of ₹16,925 Cr, is a subsidiary of the global pharma major that has delivered strong TTM sales growth of 31% but seen an 18% decline in TTM profits. The stock trades at a PE of 101.1x and 19.65x book value, while the company has maintained a consistent ROE of 21-23% over the past decade and a dividend payout of 51.4%.
- TTM revenue growth of 31% significantly outpaces the 5-year compounded sales CAGR of 23% and 10-year CAGR of 15%, indicating accelerating top-line momentum
- Consistent ROE of 21-23% across 1-year, 3-year, 5-year, and 10-year periods reflects durable capital efficiency and stable return generation
- 10-year compounded profit CAGR of 43% demonstrates exceptional long-term earnings compounding ability
- Healthy dividend payout ratio of 51.4% with a 0.52% yield signals shareholder-friendly capital allocation and confidence in cash flow generation
- Backed by AstraZeneca PLC as the parent company, providing access to a global pipeline of oncology, respiratory, and cardiovascular therapies for the Indian market
- 5-year stock CAGR of 17% and 10-year CAGR of 21% indicate sustained long-term wealth creation for shareholders
- 3-year compounded sales growth of 31% and profit growth of 15% show the business has scaled meaningfully over the medium term
- PE ratio of 101.1x is extremely elevated relative to the broader pharma sector average, leaving little margin of safety if growth disappoints
- Price-to-book ratio of 19.65x is exceptionally high, indicating the stock is priced at a steep premium to its net asset base
- TTM profit has declined 18% even as TTM sales grew 31%, pointing to significant margin compression or rising costs
- Stock price has fallen 24% over the past 1 year, underperforming the broader market and erasing recent gains
- Divergence between 3-year sales CAGR of 31% and 3-year profit CAGR of 15% suggests that revenue growth is not translating proportionally into bottom-line expansion
- As a subsidiary of a global parent, Astrazeneca Pharma India has limited control over its own product pipeline, pricing strategy, and capital allocation decisions
- Dividend yield of just 0.52% despite a 51.4% payout ratio implies the stock's valuation has stretched well beyond earnings growth, compressing yield
- 52-week high and low data are unavailable, limiting visibility into recent price range and volatility patterns for risk assessment
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
anthropic claude-opus-4.6 2h ago- NPPA overcharging notice on Betaloc Aug 25
Delhi HC stayed NPPA demand notice alleging overcharging on Betaloc-50, but AstraZeneca must deposit 15% of the demanded amount with the court registrar. Stay valid only until February 10, 2027, leaving regulatory risk unresolved.
- ESG score improved to 64 Sep 2
Crisil ESG Ratings upgraded AstraZeneca Pharma India's ESG score from 57 to 64 for FY26, a 7-point improvement within roughly a week of the earlier disclosure. Higher ESG scores can attract sustainability-focused institutional capital.
- Earlier ESG rating at 57 Aug 24
AstraZeneca Pharma India disclosed an initial Crisil ESG rating of 57 on August 24, 2026, based on public data without direct company engagement.
- Institutional investor meetings scheduled Aug 21
Company scheduled virtual one-on-one meetings with institutional investors on August 19 and August 26, 2026, disclosed under SEBI Regulation 30. Routine investor engagement with no material outcome reported.
TL;DR: AstraZeneca Pharma India's newsflow is largely routine, dominated by ESG disclosures and scheduled investor interactions. The ESG score improvement from 57 to 64 is a modest positive for institutional perception. The key risk is the unresolved NPPA overcharging notice on Betaloc-50, which remains stayed until February 2027 but carries potential financial liability. Near-term catalysts are limited; watch for the NPPA case outcome and any pipeline or earnings updates for directional clarity.
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 295 | 311 | 306 | 383 | 388 | 408 | 440 | 480 | 526 | 559 | 612 | 579 | 683 |
| Expenses | 228 | 258 | 291 | 334 | 349 | 355 | 363 | 394 | 445 | 484 | 567 | 518 | 634 |
| Operating Profit | 67 | 53 | 15 | 49 | 38 | 53 | 77 | 86 | 81 | 75 | 45 | 61 | 49 |
| OPM % | 23% | 17% | 4.9% | 13% | 10% | 13% | 17% | 18% | 15% | 13% | 7% | 11% | 7% |
| Other Income | 8 | 25 | 10 | 9 | -49 | 8 | -26 | 10 | 11 | 1 | 7 | 5 | 9 |
| Interest | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 |
| Depreciation | 4 | 4 | 4 | 4 | 4 | 9 | 9 | 18 | 17 | 3 | 4 | 6 | 5 |
| PBT | 71 | 73 | 20 | 54 | -15 | 51 | 42 | 78 | 75 | 73 | 47 | 58 | 51 |
| Tax % | 25% | 29% | 23% | 27% | -22% | 25% | 27% | 26% | 25% | 26% | 30% | 23% | 25% |
| Net Profit | 54 | 52 | 16 | 39 | -12 | 38 | 31 | 58 | 56 | 54 | 33 | 45 | 38 |
| EPS in Rs | 21.54 | 20.95 | 6.32 | 15.79 | -4.72 | 15.37 | 12.34 | 23.3 | 22.33 | 21.69 | 13.04 | 17.95 | 15.17 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 517 | 564 | 544 | 571 | 728 | 832 | 814 | 806 | 1,003 | 1,296 | 1,716 | 2,276 | 2,432 |
| Expenses | 528 | 547 | 506 | 525 | 657 | 711 | 678 | 719 | 838 | 1,111 | 1,462 | 2,014 | 2,202 |
| Operating Profit | -11 | 16 | 37 | 46 | 71 | 121 | 135 | 86 | 165 | 184 | 254 | 262 | 230 |
| OPM % | -2.2% | 2.9% | 7% | 8% | 10% | 15% | 17% | 11% | 16% | 14% | 15% | 12% | 9% |
| Other Income | 6 | 7 | 14 | 12 | 16 | 13 | 13 | 15 | -14 | 51 | -56 | 23 | 21 |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 6 |
| Depreciation | 15 | 17 | 16 | 15 | 15 | 19 | 20 | 17 | 16 | 15 | 40 | 29 | 17 |
| PBT | -21 | 6 | 36 | 44 | 73 | 114 | 127 | 83 | 134 | 220 | 156 | 252 | 228 |
| Tax % | 0% | 9% | 44% | 41% | 25% | 37% | 27% | 26% | 26% | 26% | 26% | 26% | — |
| Net Profit | -21 | 5 | 20 | 26 | 54 | 72 | 93 | 62 | 99 | 162 | 116 | 188 | 170 |
| EPS in Rs | -8.34 | 2.1 | 8.02 | 10.36 | 21.78 | 28.88 | 37.32 | 24.64 | 39.72 | 64.6 | 46.3 | 75.01 | 67.85 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 3% | 5% | 41% | 40% | 37% | 69% | 48% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves | 146 | 151 | 218 | 242 | 296 | 359 | 451 | 506 | 584 | 707 | 765 | 868 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 12 | 12 | 9 | 7 | 5 | 36 | 111 |
| Other Liabilities | 261 | 247 | 193 | 214 | 261 | 330 | 306 | 337 | 389 | 362 | 712 | 1,006 |
| Total Liabilities | 412 | 403 | 415 | 461 | 562 | 706 | 775 | 857 | 985 | 1,078 | 1,518 | 1,989 |
| Fixed Assets | 101 | 97 | 87 | 75 | 75 | 72 | 81 | 74 | 69 | 67 | 64 | 117 |
| CWIP | 12 | 6 | 5 | 4 | 7 | 24 | 4 | 2 | 1 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 298 | 299 | 324 | 382 | 480 | 611 | 690 | 780 | 915 | 1,011 | 1,454 | 1,872 |
| Total Assets | 412 | 403 | 415 | 461 | 562 | 706 | 775 | 857 | 985 | 1,078 | 1,518 | 1,989 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | -46 | 57 | 38 | 9 | 55 | 87 | 105 | 101 | 58 | 28 | 65 | -15 |
| Investing | -19 | -4 | 0 | -9 | 4 | -171 | 173 | 5 | 18 | 22 | 31 | 19 |
| Financing | 0 | -1 | 0 | 0 | 0 | -6 | -9 | -9 | -24 | -44 | -66 | -92 |
| Net Cash Flow | -64 | 53 | 38 | -1 | 59 | -90 | 269 | 96 | 52 | 5 | 31 | -88 |
| Free Cash Flow | -69 | 48 | 33 | 3 | 37 | 74 | 99 | 94 | 53 | 18 | 64 | -18 |
| CFO/OP | 393 | 365 | 133 | 28 | 126 | 100 | 101 | 146 | 60 | 46 | 51 | 26 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 30 | 54 | 29 | 35 | 40 | 37 | 38 | 39 | 39 | 43 | 39 | 34 |
| Inventory Days | 157 | 141 | 121 | 229 | 186 | 197 | 198 | 164 | 193 | 140 | 208 | 272 |
| Days Payable | 203 | 174 | 184 | 257 | 266 | 251 | 221 | 223 | 231 | 121 | 173 | 207 |
| Cash Conversion Cycle | -16 | 21 | -34 | 7 | -39 | -17 | 15 | -20 | 1 | 62 | 74 | 99 |
| Working Capital Days | -15 | -28 | -36 | -8 | -14 | -16 | -17 | -34 | -18 | 20 | 22 | 50 |
| ROCE % | -13% | 4% | 15% | 19% | 27% | 34% | 30% | 16% | 31% | 31% | 33% | 29% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view AstraZeneca Pharma insights
61 extracted metrics + investor summaries across FY10–FY26.
Documents
Frequently Asked Questions about AstraZeneca Pharma
What does Astrazeneca Pharma India Ltd do?
Where is Astrazeneca Pharma India Ltd (ASTRAZEN) listed?
Which sector does Astrazeneca Pharma India Ltd belong to?
What is the market capitalisation of Astrazeneca Pharma India Ltd?
What is the PE ratio of Astrazeneca Pharma India Ltd?
What is the 52-week high and low of Astrazeneca Pharma India Ltd?
Does Astrazeneca Pharma India Ltd pay dividends?
What is the Return on Equity (ROE) of Astrazeneca Pharma India Ltd?
Company Information
AstraZeneca Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of pharmaceutical products.[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ASTRAZEN.md for Astrazeneca Pharma India Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.